Choose your font:
 Mukta Malar
 Open Sans Condensed
 Source Sans Pro


[Valid RSS] RSS

Database - Alliance francophone pour l'accouchement respecté (AFAR)

Description of this bibliographical database (AFAR website)
Currently 3104 records
YouTube channel (tutorial)

Created on : 30 Mar 2006
Modified on : 02 Dec 2007

 Modify this record
Do not follow this link unless you know an editor’s password!

Share: Facebook logo   Tweeter logo   Hard

Bibliographical entry (without author) :

[Efficacy and safety of misoprostol in obstetrics] [Article in Spanish]. Review. {Espagne}. Farm Hosp. 2005 May-Jun;29(3):177-84.

Author(s) :

Capilla Montes C, Bermejo Vicedo T.

Year of publication :


URL(s) :…

Résumé (français)  :

Abstract (English)  :

OBJECTIVE: To review the efficacy and safety of misoprostol for indications not included in the prescription information given for the product, including abortion, labor induction, treatment and prevention of postpartum bleeding, and hysteroscopy preparation.

METHOD: Pubmed was searched for controlled, randomized, blinded clinical trials of misoprostol in obstetrics from 1999 through 2004.

RESULTS: Nineteen clinical trials were found. The efficacy for abortion in association with mifepristone at a dosage of 400 microg/6 h is superior versus both placebo and gemeprost, but misoprostol is more painful and less effective than dilation and subsequent evacuation. Regarding the administration route, trials show similar efficacy for the vaginal and oral approaches. In the prevention and treatment of postpartum hemorrhage, misoprostol was not any better than oxytocin. When used as a labor inducing agent, results are best with doses of 50 microg/3-8 h, but no controlled clinical trials were found. Although its use for hysteroscopy facilitates the procedure versus placebo, it entails a higher frequency of adverse events. No controlled clinical trials were found for other options.

CONCLUSIONS: The efficacy of misoprostol for indications reviewed in this paper is controversial, and studies found are heterogeneous. Designing and conducting further clinical trials to investigate appropriate dosage and administration routes, as well as the drug s adverse effect profile under such circumstances is essential, and would potentially allow an application for approval to be filed with health authorities regarding its use in obstetric practice.

Sumário (português)  :

Resumen (español)  :

Comments :

Argument (français) :

Argument (English):

Argumento (português):

Argumento (español):

Keywords :

➡ evidence-based medicine/midwifery ; prevention ; induction of labor ; postpartum hemorrhage ; misoprostol (Cytotec) ; post-term pregnancy ; abortion ; dilation

Author of this record :

Cécile Loup — 30 Mar 2006
➡ latest update : Marion Corbe — 02 Dec 2007

Discussion (display only in English)
➡ Only identified users

 I have read the guidelines of discussions and I accept all terms (read guidelines)


New expert query --- New simple query

Creating new record --- Importing records

User management --- Dump database --- Contact


This database is managed by Alliance francophone pour l'accouchement respecté (AFAR,
affiliated with Collectif interassociatif autour de la naissance (CIANE,
It is fed by the voluntary contributions of persons interested in the sharing of scientific data.
If you agree with this project, you can support us in several ways:
(1) contributing to this database if you have a minimum training in documentation
(2) or financially supporting AFAR (see below)
(3) or joining the AFAR (or another society affiliated with CIANE).
Sign in or create an account to follow changes or become an editor.
Contact afar.association(arobase) for more information.

Valid CSS! Valid HTML!
Donating to AFAR (click “Faire un don”) will help us to maintain and develop sites and public
databases towards the support of parents and caregivers’ informed decisions with respect to childbirth